Latest news with #NationalCancerInstitute-designated
Yahoo
2 days ago
- Business
- Yahoo
NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs
USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule Appointment bolsters FDA approval path while company explores AI and quantum computing to enhance drug delivery platform CALABASAS, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced the appointment of Josh Neman, PhD as its new Chief Clinical Officer (CCO). Dr. Neman brings with him a distinguished career at the intersection of cancer neuroscience, translational research, and academic medicine. Dr. Neman joins NeOnc Technologies Holdings Inc. (NeOnc) from the Keck School of Medicine at the University of Southern California (USC), where he serves as Associate Professor of Neurological Surgery and Physiology & Neuroscience, and Scientific Director of the USC Brain Tumor Center. At USC, he also leads the Cancer Biology and Genomics PhD Program and serves as Director of Cancer Research Training and Education Coordination at the USC Norris Comprehensive Cancer Center- a leading National Cancer Institute-designated cancer research hospital. A nationally recognized leader in neurooncological sciences and cancer neuroscience, Dr. Neman's research has advanced the understanding of how brain microenvironments influence the progression of brain tumors and metastases. His pioneering studies on tumor-neuron interactions, GABAergic signaling in cancer, and mechanisms of leptomeningeal dissemination have helped shape new therapeutic paradigms for both adult and pediatric brain tumors. 'I am deeply honored to join NeOnc at this exciting time,' said Dr. Neman. 'NeOnc's commitment to developing innovative therapeutics, including Blood Brain Barrier-penetrant compounds like NEO212 and NEO100, aligns perfectly with my lifelong passion to improve outcomes for patients with brain tumors. I look forward to helping lead the translation of promising discoveries from the lab into meaningful clinical impact.' In his role as Chief Clinical Officer, Dr. Neman will lead NeOnc's clinical development strategy, including investigator-initiated trials and precision oncology partnerships. He will also play a key role in expanding NeOnc's research collaborations with academic institutions, regulatory agencies, and patient advocacy groups. 'Dr. Neman's appointment signals a major step forward in NeOnc's mission to transform the treatment landscape for patients with life-threatening cancers with poor outcomes,' said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies Holdings, Inc. 'His academic and clinical leadership, coupled with his deep expertise in brain tumor biology, will be instrumental in accelerating all four of our clinical trials—especially our lead asset, NEO100, which is approaching the completion of its Phase 2a trial with full enrollment achieved ahead of schedule. As we look to add AI and quantum computing into our expanding platform in drug delivery and bio-conjugation, Dr. Neman's appointment further strengthens our commitment to advancing precision therapies and driving toward FDA approval.' About NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI): NeOnc Technologies is a publicly traded, clinical-stage biopharmaceutical company developing innovative therapies for brain and central nervous system cancers. Its lead programs—NEO100-01, NEO100-02, NEO100-03, and NEO212—utilize proprietary formulations to bypass the blood-brain barrier and target malignancies with precision. The company's IP portfolio includes 176 patents worldwide, reflecting a broad platform with strong commercialization potential. For more about NeOnc and its pioneering technology, visit Important Cautions Regarding Forward-Looking Statements All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate," or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law. 'NEO100' is a registered trademark of NeOnc Technologies Holdings, Inc. Company Contact:23975 Sorrento Park Suite 205, Calabasas, CA, 91302info@ Investor Relations:James CarbonaraHayden IR369 Lexington AvenueSecond FloorNew York, NY 10017Office: (646)-755-7412James@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
4 days ago
- Health
- Miami Herald
What patients can expect from the new leader of a South Florida hospital system
The University of Miami Health System has a new leader. Dr. Dipen Parekh, a surgeon who led the hospital system through the COVID-19 pandemic, will now serve as UHealth's chief executive officer and UM's executive vice president for Health Affairs. As UHealth CEO, Parekh will oversee the more than 17,500 employees who work across the hospital system at more than 100 facilities, including Bascom Palmer Institute, the nation's top hospital for opthalmology, and Sylvester Comprehensive Cancer Center, the only National Cancer Institute-designated cancer center in South Florida. The urologic oncologist wants UM to 'push the frontiers of research.' That goal may be challenging at a time when more than 1,000 research grants in the country have been terminated by the federal government, according to a database created by two scientists documenting the terminations and as reported by STAT News. Parekh also sees more AI in the future of healthcare in South Florida. 'The demand for our services is increasing every day, and our responsibility is to meet that demand without compromising the excellence that defines UHealth,' Parekh told the Miami Herald Wednesday in an email. 'To do so, we must continue to improve how patients access our care—whether that's through new locations, more efficient systems, or advanced technologies. Artificial intelligence will play a key role in this effort. 'AI holds tremendous promise in helping us make smarter decisions, improve outcomes, and enhance the experience for both patients and providers.' UM's Board of Trustees unanimously agreed this week to promote Parekh, UHealth's chief operating officer and a longtime urology chair at UM's medical school, to CEO. The surgeon will takes over the top job from Joseph Echevarria, who since 2024 has juggled the jobs of UM and UHealth president and UHealth CEO. Echevarria will remain president. Parekh considers expansion to be one of the health system's greatest challenges — and opportunities — and has played a key role in UHealth's recent push into North Miami-Dade and Doral, one of South Florida's hottest growing medical hubs. Like other health systems, UHealth is trying to bring care closer to patients, a strategy to not only improve access to care, but to also attract and retain patients and employees. 'Dipen has played a pivotal role each step of the way as the University of Miami Health System has grown into one of the top academic medical centers in the country,' Echevarria said in a statement. 'He understands the mission —from the operating room to the classroom to the boardroom — and he embodies the excellence we strive to deliver for our patients, students, and community.' Who is UHealth's new CEO? UHealth is now the second hospital system in South Florida to be currently led by a physician. The veteran surgeon, one of UM's highest paid employees, has performed more than 6,000 robotic urologic cancer surgeries and has published more than 200 peer-reviewed publications, including a 'groundbreaking trial, published in The Lancelet in 2018, which established the efficacy of robotic-assisted surgery for bladder cancer,' according to the university. Parekh joined UM's medical school in 2012 as the chair of urology and is also the founding director of the Desai Seithi Urology Institute. He became chief clinical officer, his first system-wide administrative role, in 2017, before becoming chief operating officer in 2020, when COVID struck and hospitals became overwhelmed with sick patients. Besides being tasked with overseeing UHealth's day-to-day operations, Parekh in 2021 was also made executive dean for clinical affairs at UM's Miller School of Medicine. Becker's Hospital Review named him among the top 60 academic health system COO's to know in 2024. The private university declined to reveal is new salary. For years, UHealth has been the only academic health system in South Florida although that will change once Baptist Health South Florida finalizes the process of becoming the future teaching hospital of Florida International University. FIU has tapped Nicklaus Children's Health System to be its pediatric teaching hospital. UHealth's teaching hospital is Jackson Memorial, part of Miami-Dade's public hospital network. At UM's medical school and health system, researchers have long tackled infectious diseases, cancer treatments and therapies, Alzheimer's, dementia, genetic diseases and many other conditions. The Miami Project to Cure Paralysis is working with Elon Musk's startup company Neuralink to test whether its brain chip can give people who are paralyzed the ability to use mind to wirelessly control computers, smartphones and other electronic devices. 'Our role as an academic health system is not just to care for patients, but to lead in innovation, discovery, and training the next generation of healthcare leaders,' said Parekh, who plans to keep caring for patients while serving as CEO. 'That's what sets us apart — and that's what we'll continue to build on.'
Business Wire
6 days ago
- Health
- Business Wire
Run, Fundraise, Inspire: Be Part of the 2025 St. Jude Memphis Marathon Weekend
MEMPHIS, Tenn.--(BUSINESS WIRE)--Registration opens June 4 for the 2025 St. Jude Memphis Marathon ® Weekend presented by Juice Plus+, the largest single-day fundraising event for St. Jude Children's Research Hospital ®. Set for Saturday, Dec. 6, marathon weekend brings together tens of thousands of runners, volunteers and supporters from all 50 states and representing more than 75 countries. Organizers aim to raise $16 million through this year's event to help St. Jude continue advancing research and treatment for childhood cancer and other life-threatening diseases. 'Witnessing the power of people from around the world coming together for St. Jude is awe-inspiring every single year,' said Ike Anand, interim CEO of ALSAC, the fundraising and awareness organization for St. Jude Children's Research Hospital. 'When participants run, fundraise, take time to volunteer or join our cheer program, they're choosing to help give children a chance to live their best lives and celebrate every moment. Every mile, every donation, and every act of support helps ensure no family receives a bill from St. Jude for treatment, travel, housing, or food. That's the impact we make together.' Here's how to get involved: Run. Sign up for the marathon, half marathon, 10K or 5K—individually or as a team, Duo, Guided Runner, or Wheelchair Participant. Click here to learn more about assisted in-person participation. Fundraise. Raise funds while running in Memphis or virtually. Participants receive a personal fundraising link following registration. Give. Donate to a participant or directly to our event goal. Volunteer. Become one of more than 4,000 volunteers who help make race day possible. General registration opens in August. Cheer. Join the cheer program to bring energy, encouragement, and support to runners. Registration opens in August. Funds raised from events like this marathon enable St. Jude to support more families in the United States while accelerating programs to help the 400,000 children worldwide who develop cancer each year. These efforts include the recent delivery of free cancer medicines to children in five countries as part of a global collaboration, and new research findings by St. Jude on how to protect the bone health of childhood cancer survivors. Participate, fundraise, volunteer, or cheer—visit to support St. Jude today. St. Jude Children's Research Hospital ® St. Jude Children's Research Hospital is leading the way the world understands, treats and defeats childhood cancer and other life-threatening diseases. Its purpose is clear: Finding cures. Saving children. ® It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. When St. Jude opened in 1962, childhood cancer was largely considered incurable. Since then, St. Jude has helped push the overall survival rate from 20% to more than 80%, and it won't stop until no child dies from cancer. St. Jude shares the breakthroughs it makes to help doctors and researchers at local hospitals and cancer centers around the world improve the quality of treatment and care for even more children. Because of generous donors, families never receive a bill from St. Jude for treatment, travel, housing or food, so they can focus on helping their child live. Visit St. Jude Inspire to discover powerful St. Jude stories of hope, strength, love and kindness. Support the St. Jude mission by donating at liking St. Jude on Facebook, following St. Jude on X, Instagram, LinkedIn and TikTok, and subscribing to its YouTube channel.
Business Wire
05-05-2025
- Entertainment
- Business Wire
The 23rd Annual FedEx/St. Jude Angels and Stars Gala Raises $900,000 for St. Jude Children's Research Hospital
MIAMI--(BUSINESS WIRE)--On the evening of May 3rd, the stars aligned at the Hotel InterContinental for the 23rd annual FedEx/St. Jude Angels and Stars Gala. The event benefiting St. Jude Children's Research Hospital ® brought together St. Jude patient families, numerous celebrities, and South Florida's most dedicated philanthropic community members. Together, they celebrated the remarkable achievements of St. Jude since its founding in 1962 and raised over $900,000 to ensure families never receive a bill from St. Jude for treatment, travel, housing or food – so they can focus on helping their child live. Sponsors included FedEx, Genesis Fortune, LLC, and Bomnin Automotive Group, among others. The FedEx/St. Jude Angels and Stars Gala began as an ambitious dream twenty-three years ago. Today, it continues to inspire philanthropists who unite to support the St. Jude mission of advancing cures and prevention for pediatric catastrophic diseases through research and treatment. This year's gala featured keynote speaker Dr. Victor Torres, Chair, Department of Host-Microbe Interactions, who spoke to guests about the incredible progress being made daily at St. Jude and how its groundbreaking research is shared globally. Guests also enjoyed a captivating performance by The Culture Band and an exciting live auction, which includes Paris Fashion Week tickets to the Givenchy Fashion Show and Private Celebrity Chef Dinner experiences by renowned chefs Lorena Garcia and Jesus Diaz. Celebrity attendees included TelevisaUnivision anchor Pamela Silva, Sientese Quien Pueda's Stephanie Himonidis, En Casa Con Telemundo's Carlos Adyan, Chef Jesus Diaz, Chef Lorena Garcia and many more. Donate to St. Jude at St. Jude Children's Research Hospital ® St. Jude Children's Research Hospital is leading the way the world understands, treats, and defeats childhood cancer and other life-threatening diseases. Its purpose is clear: Finding cures. Saving children.® It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. When St. Jude opened in 1962, childhood cancer was largely considered incurable. Since then, St. Jude has helped push the overall survival rate from 20% to more than 80%, and it won't stop until no child dies from cancer. St. Jude shares the breakthroughs it makes to help doctors and researchers at local hospitals and cancer centers around the world improve the quality of treatment and care for even more children. Because of generous donors, families never receive a bill from St. Jude for treatment, travel, housing, or food, so they can focus on helping their child live. Visit St. Jude Inspire to discover powerful St. Jude stories of hope, strength, love and kindness. Support the St. Jude mission by donating at liking St. Jude on Facebook, following St. Jude on X, Instagram, LinkedIn and TikTok, and subscribing to its YouTube channel.
Yahoo
02-05-2025
- Health
- Yahoo
Trump budget proposal calls for deep cuts to NIH
WASHINGTON (NEXSTAR) – The U.S. Senate Appropriations Committee highlighted this week the harms of potential Trump administration cuts to the National Institutes of Health in an attempt to stop them. U.S. Sen. Cindy Hyde-Smith (R-Miss.) advocated for the University of Mississippi Medical Center's efforts to become a National Cancer Institute-designated center. Currently, there are none in her state or surrounding ones, including Louisiana and Arkansas. 'This situation requires Mississippians to travel distances for advanced cancer care,' said Hyde-Smith. 'As your neighbor, I understand the cancer burdens that your state experiences very, very well,' said Dr. Barry Paul Sleckman, the director of the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, which does have the NCI designation. Sleckman told the committee potential funding cuts would slow these opportunities for new research and treatments. 'Those will have to stay holding for a longer period of time,' he said. The Trump administration unveiled its 2026 budget proposal Friday, which calls on Congress to slash the overall NIH budget nearly in half, from about $48 billion to $30 billion. 'There have not been any actual cuts,' said NIH Director Dr. Jay Bhattacharya. Instead, Bhattacharya said the agency is going through 'a reprioritization.' 'To focus on the diseases actually inflicting the American people,' he said. 'So it's not to take away money. It's quite the opposite.' The budget proposal maintains $27 billion for NIH research but did not detail the funds. The U.S. Senate Health Committee is holding a hearing on the president's budget Wednesday, where HHS Secretary Robert F. Kennedy Jr., who oversees the NIH, plans to testify. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
